nach oben

Erschienen in:

11.03.2016 | Original Article

Cyclosporine restores hematopoietic function by compensating for decreased Tregs in patients with pure red cell aplasia and acquired aplastic anemia

verfasst von: An T. T. Dao, Hirohito Yamazaki, Hiroyuki Takamatsu, Chiharu Sugimori, Takamasa Katagiri, Hiroyuki Maruyama, Yoshitaka Zaimoku, Kana Maruyama, Trung Q. Ly, Luis Espinoza, Shinji Nakao

Erschienen in: Annals of Hematology | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

Most patients with acquired pure red cell aplasia (PRCA) and some with acquired aplastic anemia (AA) respond well to cyclosporine (CsA), but thereafter often show CsA dependency. The mechanism underlying this dependency remains unknown. We established a reliable method for measuring the regulatory T cell (Treg) count using FoxP3 and Helios expression as markers and determined the balance between Tregs and other helper T cell subsets in 16 PRCA and 29 AA patients. The ratios of interferon-γ-producing CD4⁺ (Th1) T cells to Tregs in untreated patients and CsA-dependent patients were significantly higher (PRCA 5.77 ± 1.47 and 7.38 ± 2.58; AA 6.18 ± 2.35 and 8.94 ± 4.06) than in healthy volunteers (HVs; 3.33 ± 0.90) due to the profound decrease in the percentage of Tregs. In contrast, the ratios were comparable to HVs in convalescent CsA-treated AA patients (4.74 ± 2.10) and AA patients in remission after the cessation of CsA treatment (4.24 ± 1.67). Low-dose CsA (100 ng/ml) inhibited the proliferation of conventional T cells (Tconv) to a similar degree to the inhibition by Tregs in a co-culture with a 1:1 Treg/Tconv ratio. The data suggest that CsA may reverse the hematopoietic suppression in PRCA and AA patients by compensating for the inadequate immune regulatory function that occurs due to a profound decrease in the Treg count.

Nur mit Berechtigung zugänglich

Nitta H, Mihara K, Sakai A, Kimura A (2010) Expansion of CD8+ /perforin+ effector memory T cells in the bone marrow of patients with thymoma-associated pure red cell aplasia. Br J Haematol 150(6):712–715. doi:10.1111/j.1365-2141.2010.08273.x CrossRefPubMed

Nitta H, Harada Y, Hyodo H, Kimura A, Harada H (2012) Expansion of CD8+/perforin+ T-cells predicts response to ciclosporin A therapy in patients with erythroid hypoplasia/aplasia. Br J Haematol 157(5):641–645. doi:10.1111/j.1365-2141.2012.09057.x CrossRefPubMed

Michishita Y, Hirokawa M, Fujishima N, Abe Y, Fujishima M, Guo YM, Ubukawa K, Liu J, Yoshioka T, Kameoka Y, Saitoh H, Tagawa H, Takahashi N, Sawada K (2013) CDR3-independent expansion of Vdelta1 T lymphocytes in acquired chronic pure red cell aplasia. Immunol Lett 150(1–2):23–29. doi:10.1016/j.imlet.2012.12.006 CrossRefPubMed

Fujishima N, Hirokawa M, Fujishima M, Wada C, Toyoshima I, Watanabe S, Sawada K (2006) Oligoclonal T cell expansion in blood but not in the thymus from a patient with thymoma-associated pure red cell aplasia. Haematologica 91(12 Suppl):ECR47PubMed

Shinohara K, Mitani N, Miyazaki M, Sakuragi S, Matsuda K, Ogawara S, Saito T, Kaneoka H, Ooji T (2005) Pure red-cell aplasia caused by the antibody to recombinant erythropoietin, epoetin-beta, in a Japanese patient with chronic renal failure. Am J Hematol 78(1):15–20. doi:10.1002/ajh.20245 CrossRefPubMed

Aljama P, Carracedo J, Madueno JA, Ramirez R, Martin-Malo A, de Francisco AL M (2005) Antibody-mediated pure red cell aplasia (PRCA): ensuring future progress by collecting data from a registry. Nephrol Dial Transplant: Off Publ Eur Dial Transplant Assoc Eur Ren Assoc 20(Suppl 4):iv27-30. doi:10.1093/ndt/gfh1089

Sawada K, Hirokawa M, Fujishima N, Teramura M, Bessho M, Dan K, Tsurumi H, Nakao S, Urabe A, Omine M, Ozawa K, Group PCS (2007) Long-term outcome of patients with acquired primary idiopathic pure red cell aplasia receiving cyclosporine A. A nationwide cohort study in Japan for the PRCA Collaborative Study Group. Haematologica 92(8):1021–1028CrossRefPubMed

Saracco P, Quarello P, Iori AP, Zecca M, Longoni D, Svahn J, Varotto S, Del Vecchio GC, Dufour C, Ramenghi U, Bacigalupo A, Locasciulli A, Bone Marrow Failure Study Group of the A (2008) Cyclosporin A response and dependence in children with acquired aplastic anaemia: a multicentre retrospective study with long-term observation follow-up. Br J Haematol 140(2):197–205. doi:10.1111/j.1365-2141.2007.06903.x CrossRefPubMed

Nakao S, Takamatsu H, Chuhjo T, Ueda M, Shiobara S, Matsuda T, Kaneshige T, Mizoguchi H (1994) Identification of a specific HLA class II haplotype strongly associated with susceptibility to cyclosporine-dependent aplastic anemia. Blood 84(12):4257–4261PubMed

10.

Buckner JH (2010) Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat Rev Immunol 10(12):849–859. doi:10.1038/nri2889 CrossRefPubMedPubMedCentral

11.

Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, Fehervari Z, Shimizu J, Takahashi T, Nomura T (2006) Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 212:8–27. doi:10.1111/j.0105-2896.2006.00427.x CrossRefPubMed

12.

Kordasti S, Marsh J, Al-Khan S, Jiang J, Smith A, Mohamedali A, Abellan PP, Veen C, Costantini B, Kulasekararaj AG, Benson-Quarm N, Seidl T, Mian SA, Farzaneh F, Mufti GJ (2012) Functional characterization of CD4+ T cells in aplastic anemia. Blood 119(9):2033–2043. doi:10.1182/blood-2011-08-368308 CrossRefPubMed

13.

Shi J, Ge M, Lu S, Li X, Shao Y, Huang J, Huang Z, Zhang J, Nie N, Zheng Y (2012) Intrinsic impairment of CD4(+)CD25(+) regulatory T cells in acquired aplastic anemia. Blood 120(8):1624–1632. doi:10.1182/blood-2011-11-390708 CrossRefPubMed

14.

Kim YC, Bhairavabhotla R, Yoon J, Golding A, Thornton AM, Tran DQ, Shevach EM (2012) Oligodeoxynucleotides stabilize Helios-expressing Foxp3+ human T regulatory cells during in vitro expansion. Blood 119(12):2810–2818. doi:10.1182/blood-2011-09-377895 CrossRefPubMedPubMedCentral

15.

Raffin C, Pignon P, Celse C, Debien E, Valmori D, Ayyoub M (2013) Human memory Helios− FOXP3+ regulatory T cells (Tregs) encompass induced Tregs that express Aiolos and respond to IL-1beta by downregulating their suppressor functions. J Immunol 191(9):4619–4627. doi:10.4049/jimmunol.1301378 CrossRefPubMed

16.

Golding A, Hasni S, Illei G, Shevach EM (2013) The percentage of FoxP3+Helios+ Treg cells correlates positively with disease activity in systemic lupus erythematosus. Arthritis Rheum 65(11):2898–2906. doi:10.1002/art.38119 CrossRefPubMedPubMedCentral

17.

Bin Dhuban K, d’Hennezel E, Nashi E, Bar-Or A, Rieder S, Shevach EM, Nagata S, Piccirillo CA (2015) Coexpression of TIGIT and FCRL3 identifies Helios+ human memory regulatory T cells. J Immunol 194(8):3687–3696. doi:10.4049/jimmunol.1401803 CrossRefPubMed

18.

Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, Parizot C, Taflin C, Heike T, Valeyre D, Mathian A, Nakahata T, Yamaguchi T, Nomura T, Ono M, Amoura Z, Gorochov G, Sakaguchi S (2009) Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 30(6):899–911. doi:10.1016/j.immuni.2009.03.019 CrossRefPubMed

19.

Solomou EE, Rezvani K, Mielke S, Malide D, Keyvanfar K, Visconte V, Kajigaya S, Barrett AJ, Young NS (2007) Deficient CD4+ CD25+ FOXP3+ T regulatory cells in acquired aplastic anemia. Blood 110(5):1603–1606. doi:10.1182/blood-2007-01-066258 CrossRefPubMedPubMedCentral

20.

de Latour RP, Visconte V, Takaku T, Wu C, Erie AJ, Sarcon AK, Desierto MJ, Scheinberg P, Keyvanfar K, Nunez O, Chen J, Young NS (2010) Th17 immune responses contribute to the pathophysiology of aplastic anemia. Blood 116(20):4175–4184. doi:10.1182/blood-2010-01-266098 CrossRefPubMedPubMedCentral

21.

Ryba-Stanislawowska M, Rybarczyk-Kapturska K, Mysliwiec M, Mysliwska J (2014) Elevated levels of serum IL-12 and IL-18 are associated with lower frequencies of CD4(+)CD25 (high)FOXP3 (+) regulatory T cells in young patients with type 1 diabetes. Inflammation 37(5):1513–1520. doi:10.1007/s10753-014-9878-1 CrossRefPubMedPubMedCentral

22.

Bovenschen HJ, van de Kerkhof PC, van Erp PE, Woestenenk R, Joosten I, Koenen HJ (2011) Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin. J Invest Dermatol 131(9):1853–1860. doi:10.1038/jid.2011.139 CrossRefPubMed

23.

Bovenschen HJ, van Vlijmen-Willems IM, van de Kerkhof PC, van Erp PE (2006) Identification of lesional CD4+ CD25+ Foxp3+ regulatory T cells in psoriasis. Dermatology 213(2):111–117. doi:10.1159/000093849 CrossRefPubMed

24.

Thornton AM, Korty PE, Tran DQ, Wohlfert EA, Murray PE, Belkaid Y, Shevach EM (2010) Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J Immunol 184(7):3433–3441. doi:10.4049/jimmunol.0904028 CrossRefPubMedPubMedCentral

25.

Himmel ME, MacDonald KG, Garcia RV, Steiner TS, Levings MK (2013) Helios+ and Helios− cells coexist within the natural FOXP3+ T regulatory cell subset in humans. J Immunol 190(5):2001–2008. doi:10.4049/jimmunol.1201379 CrossRefPubMed

26.

Coenen JJ, Koenen HJ, van Rijssen E, Hilbrands LB, Joosten I (2006) Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells. Blood 107(3):1018–1023. doi:10.1182/blood-2005-07-3032 CrossRefPubMed

27.

Zeiser R, Nguyen VH, Beilhack A, Buess M, Schulz S, Baker J, Contag CH, Negrin RS (2006) Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 108(1):390–399. doi:10.1182/blood-2006-01-0329 CrossRefPubMedPubMedCentral

28.

Baumgrass R, Brandt C, Wegner F, Abdollahnia M, Worm M (2010) Low-dose, but not high-dose, cyclosporin A promotes regulatory T-cell induction, expansion, or both. J Allergy Clin Immunol 126(1):183–184. doi:10.1016/j.jaci.2010.04.032, author reply 184 CrossRefPubMed

29.

Brandt C, Pavlovic V, Radbruch A, Worm M, Baumgrass R (2009) Low-dose cyclosporine A therapy increases the regulatory T cell population in patients with atopic dermatitis. Allergy 64(11):1588–1596. doi:10.1111/j.1398-9995.2009.02054.x CrossRefPubMed

30.

Kawai M, Kitade H, Mathieu C, Waer M, Pirenne J (2005) Inhibitory and stimulatory effects of cyclosporine A on the development of regulatory T cells in vivo. Transplantation 79(9):1073–1077CrossRefPubMed

31.

Fanigliulo D, Lazzerini PE, Capecchi PL, Ulivieri C, Baldari CT, Laghi-Pasini F (2015) Clinically-relevant cyclosporin and rapamycin concentrations enhance regulatory T cell function to a similar extent but with different mechanisms: an in-vitro study in healthy humans. Int Immunopharmacol 24(2):276–284. doi:10.1016/j.intimp.2014.12.021 CrossRefPubMed

32.

Fujisao S, Tsuda H (1998) Th1/Th2 balance alteration in the clinical course of a patient with pure red cell aplasia and thymoma. Br J Haematol 103(2):308–310CrossRefPubMed

33.

Alunno A, Manetti M, Caterbi S, Ibba-Manneschi L, Bistoni O, Bartoloni E, Valentini V, Terenzi R, Gerli R (2015) Altered immunoregulation in rheumatoid arthritis: the role of regulatory T cells and proinflammatory th17 cells and therapeutic implications. Mediat Inflamm 2015:751793. doi:10.1155/2015/751793

34.

Noack M, Miossec P (2014) Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun Rev 13(6):668–677. doi:10.1016/j.autrev.2013.12.004 CrossRefPubMed

35.

Dolff S, Bijl M, Huitema MG, Limburg PC, Kallenberg CG, Abdulahad WH (2011) Disturbed Th1, Th2, Th17 and T(reg) balance in patients with systemic lupus erythematosus. Clin Immunol 141(2):197–204. doi:10.1016/j.clim.2011.08.005 CrossRefPubMed

36.

Buc M (2013) Role of regulatory T cells in pathogenesis and biological therapy of multiple sclerosis. Mediat Inflamm 2013:963748. doi:10.1155/2013/963748 CrossRef

37.

Sawada K, Fujishima N, Hirokawa M (2008) Acquired pure red cell aplasia: updated review of treatment. Br J Haematol 142(4):505–514. doi:10.1111/j.1365-2141.2008.07216.x CrossRefPubMedPubMedCentral

38.

Hirokawa M, Sawada K, Fujishima N, Nakao S, Urabe A, Dan K, Fujisawa S, Yonemura Y, Kawano F, Omine M, Ozawa K, Group PCS (2008) Long-term response and outcome following immunosuppressive therapy in thymoma-associated pure red cell aplasia: a nationwide cohort study in Japan by the PRCA collaborative study group. Haematologica 93(1):27–33. doi:10.3324/haematol.11655 CrossRefPubMed

39.

Philippe M, Henin E, Bertrand Y, Plantaz D, Goutelle S, Bleyzac N (2015) Model-based determination of effective blood concentrations of cyclosporine for neutrophil response in the treatment of severe aplastic anemia in children. AAPS J 17(5):1157–1167. doi:10.1208/s12248-015-9779-8 CrossRefPubMed

40.

Samson M, Audia S, Janikashvili N, Ciudad M, Trad M, Fraszczak J, Ornetti P, Maillefert JF, Miossec P, Bonnotte B (2012) Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. Arthritis Rheum 64(8):2499–2503. doi:10.1002/art.34477 CrossRefPubMed

41.

Bell CJ, Sun Y, Nowak UM, Clark J, Howlett S, Pekalski ML, Yang X, Ast O, Waldhauer I, Freimoser-Grundschober A, Moessner E, Umana P, Klein C, Hosse RJ, Wicker LS, Peterson LB (2015) Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells. J Autoimmun 56:66–80. doi:10.1016/j.jaut.2014.10.002 CrossRefPubMedPubMedCentral

42.

Zorn E, Nelson EA, Mohseni M, Porcheray F, Kim H, Litsa D, Bellucci R, Raderschall E, Canning C, Soiffer RJ, Frank DA, Ritz J (2006) IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 108(5):1571–1579. doi:10.1182/blood-2006-02-004747 CrossRefPubMedPubMedCentral

43.

Xia J, Liu W, Hu B, Tian Z, Yang Y (2010) IL-15 promotes regulatory T cell function and protects against diabetes development in NK-depleted NOD mice. Clin Immunol 134(2):130–139. doi:10.1016/j.clim.2009.09.011 CrossRefPubMed

Titel: Cyclosporine restores hematopoietic function by compensating for decreased Tregs in patients with pure red cell aplasia and acquired aplastic anemia
verfasst von: An T. T. Dao
Hirohito Yamazaki
Hiroyuki Takamatsu
Chiharu Sugimori
Takamasa Katagiri
Hiroyuki Maruyama
Yoshitaka Zaimoku
Kana Maruyama
Trung Q. Ly
Luis Espinoza
Shinji Nakao
Publikationsdatum: 11.03.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Annals of Hematology / Ausgabe 5/2016
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-016-2629-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2016

Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCR

Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH)

Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN) using the Delphi method

Rituximab is an effective and safe treatment of relapse in elderly patients with resistant warm AIHA

Evaluation of clinicopathologic characteristics and the BRAF V600E mutation in Erdheim-Chester disease among Chinese adults